CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Coronary flow velocity reserve predicts adverse prognosis in women with angina and noobstructive coronary artery disease: resultsfrom the iPOWER study Optimal Stenting Technique for Complex Coronary Lesions Intracoronary Imaging-Guided Pre-Dilation, Stent Sizing, and Post-Dilation A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion The REVASC Trial Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Cardiovascular Biomarkers and Imaging in Older Adults: JACC Council Perspectives Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months versus aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights
|<<... 53 54 55 56 57 58 59 ...>>|

Original Research

JOURNAL：CBSMD Article Link

心脏代谢临床试验中的黑洞 —— 不明原因死亡

CBSMD Keywords: cardivascular system; clinical study; trial design

Pre-reading

现代心脏代谢临床试验常将心血管死亡作为主要研究复合终点事件的一部分，由临床事件委员会（clinical event committees， CEC）明确死因。因可掌握信息不充分而无法判定死因的情况时有发生，属于临床试验终点事件的黑洞区域。 US FDA对经营管理好的临床试验的其中一项评价标准是无法明确死因的发生率应控制在罕见范围，而现实并非如此。“Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials”对9项心脏代谢临床试验的死亡原因进行了汇总分析，评估其中不明原因死亡（undetermined death）的发生率。


同期发表在《循环》上的评论文章“Classification of Deaths in Cardiovascular Outcomes Trials”

1. 介绍了心脏代谢临床试验将死亡分为心源性死亡及非心源性死亡这一通用做法的原因；

2. 指出在使用随机、对照、设盲临床设计评估新疗法有效性和安全性的同时，虽然可能的试验偏差可通过好的试验设计得以有效的规避，但对那些已知范围外未知的把控也体现了一项优质临床试验的科研质控水平。

3. 罗列了不同试验操作系统中导致无法判定死因的数量产生变化的三种情形：
(1)    完整记录缺失或死亡判定原因不充分；
(2)    死亡过程不可知(例如独居者死亡时间不确定且未经尸检明确)；
(3)    研究人员获得完整数据受限(例如随访知情同意撤回)。
4. 建议可通过加大对不明原因死亡事件的管理，进一步提高未来临床试验的数据质量，才能有效地通过试验得出心血管疗法是否确为安全或有效。


>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top